Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469228 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL27523505 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL28853875 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL236473 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL7273267 | 0.65 | — | — | |
| SCHEMBL4768341 | 0.64 | — | — | |
| SCHEMBL4629715 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL4148794 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL29223356 | 0.62 | — | — | |
| SCHEMBL7021307 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093625-B2 | Process for the preparation of [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-09 | — | — | US | claimed |
| US-20170247328-A1 | IMPROVED PROCESS FOR THE PREPARATION OF [[2(S)-[[4(R)-(3-HYDROXYPHENYL)-3(R),4-DIMETHYL-1-PIPERIDINYL]METHYL]-1-OXO-3-PHENYLPROPYL]AMINO]ACETIC ACID DIHYDRATE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-08-31 | — | — | US | claimed |
| US-20230364270-A1 | LIPOSOME-ASSISTED IMAGING OF VASCULAR INFLAMMATION | HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ (FI) | 2023-11-16 | — | — | US | disclosed |
| EP-4192520-A1 | LIPOSOME-ASSISTED IMAGING OF VASCULAR INFLAMMATION | Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä (FI) | 2023-06-14 | — | — | EP | disclosed |
| EP-3986400-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | Naurex Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020263848-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | NAUREX INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2415802-B1 | NOVEL ACYL ACIDIC AMINO ACID ESTER | AJINOMOTO KK (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-10093625-B2 | Process for the preparation of [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-09 | — | — | US | disclosed |
| US-20170247328-A1 | IMPROVED PROCESS FOR THE PREPARATION OF [[2(S)-[[4(R)-(3-HYDROXYPHENYL)-3(R),4-DIMETHYL-1-PIPERIDINYL]METHYL]-1-OXO-3-PHENYLPROPYL]AMINO]ACETIC ACID DIHYDRATE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| US-8399524-B2 | Acyl acidic amino acid ester | AJINOMOTO CO., INC. (JP) | 2013-03-19 | — | — | US | disclosed |
| CN-102958937-A | Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors | LEO PHARMA AS | 2013-03-06 | — | — | CN | disclosed |
| US-20120071570-A1 | NOVEL ACYL ACIDIC AMINO ACID ESTER | AJINOMOTO CO., INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2415802-A1 | NOVEL ACYL ACIDIC AMINO ACID ESTER | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-7887835-B2 | for vascular lesion imaging and for diagnosing arteriosclerosis, ischemia with X-ray angiography and positron emission tomography; fluorinated steroid ester, glyceride compounds, phosphatidylcholine, and phosphatidylserine as membrane components of liposome | FUJIFILM CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20080138285-A1 | Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound | FUJIFILM CORPORATION (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1916255-A2 | Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound | FUJIFILM Corporation (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-0836613-B1 | WATER-SOLUBLE ADENOSINE KINASE INHIBITORS | METABASIS THERAPEUTICS INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-5795977-A | Water soluble adenosine kinase inhibitors | METABASIS THERAPEUTICS, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0836613-A1 | WATER-SOLUBLE ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1996040707-A1 | WATER-SOLUBLE ADENOSINE KINASE INHIBITORS | GENSIA SICOR (US) | 1996-12-19 | — | — | WO | disclosed |